Q-omics provides the consensus-scored TCEANC2 profile across patient tissues and cancer cell-line models. TCEANC2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TCEANC2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TCEANC2 RNA expression shows 20,605 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, THCA, and ACC as cancer lineages where TCEANC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEANC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEANC2 survival associations across molecular data types. TCEANC2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEANC2 RNA expression–survival associations across cancer types. High TCEANC2 expression shows unfavorable associations in LIHC, KICH, ACC and LGG, but favorable associations in KIRC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TCEANC2 RNA expression.
This table summarizes TCEANC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TCEANC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEANC2 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, BLCA and STAD. The THCA box plot shows higher TCEANC2 RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with TCEANC2 in patient tissues and cancer cell lines. In patient samples, TCEANC2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEANC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
